Calliditas Therapeutics IPO Presentation Deck
Investment highlights
1 Nefecon is a proprietary, novel treatment for IgAN intended to be disease modifying
Nefecon targets the presumed origin of the disease - the area of the ileum where the highest
concentration of Peyer's patches are located
2
3
4
5
6
7
Nefecon is the most advanced product candidate for IgAN. The only successful randomized,
double-blind, placebo-controlled Phase 2b clinical trial carried out in IgAN to date
Ongoing pivotal Phase 3 clinical trial (NeflgArd) using the same primary endpoint as previous
successful Phase 2b trial
Regulatory pathway based on FDA and EMA acceptance of accelerated / conditional approval
based on proteinuria as surrogate marker for IgAN
Significant unmet medical need in IgAN with no currently approved treatments; total market
opportunity of US$9-10bn in the U.S alone.
Additional potential for pipeline development and in-licensing of product candidates targeting
orphan diseases
calliditas
410
300 1600
200
n
100
June 2020
32View entire presentation